CellaVision AB (STU:C26)
€ 18.64 0.88 (4.95%) Market Cap: 454.18 Mil Enterprise Value: 445.31 Mil PE Ratio: 33.07 PB Ratio: 6.46 GF Score: 99/100

Q4 2019 CellaVision AB Earnings Call Transcript

Feb 05, 2020 / 10:00AM GMT
Release Date Price: €32.05 (+0.16%)
Zlatko Rihter;publ;President;CEO
CellaVision AB

()-&

Good morning, everybody. Zlatko Rihter here from Lund. I'm here together with Maria Morin who is Head of the Corporate Communications and IR here at CellaVision; and also Magnus Blixt who is the CFO. So -- and he, myself -- and I, Zlatko Rihter.

So basically, what I will do today is I'll go through the presentation as I usually do. Just a quick comment initially, as you know that we closed the transaction of RAL Diagnostics, October 1. And that also means that all of their sales and all of their numbers are included in the Q4 report. So it's a little bit of a new CellaVision that emerges now. And of course, we'll try to comment as much as possible on that also.

So my suggestion is that we move to Slide #3. And even if we have a new world up there with RAL included, still the mission we have from CellaVision's perspective as corporation is still the same, we strongly believe that by replacing traditional microscopes, preferably or initially now in hematology labs, we create value, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot